RCT | Adjuvant oral ibandronate does not improve outcomes in postmenopausal women with estrogen receptor–positive breast cancer.

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Adjuvant Ibandronate Not Beneficial for ER+ Breast Cancer – Cancer Therapy Advisor

Commentary on Twitter

New phase 3 trial of adjuvant bisphosphonates for ER+ eBC published on @JCO_ASCO.
1,116 patients randomized to ET +/- 3 years of ibandronate. No DFS benefit (HR 0.97, p=0.81). Eleven patients in the ibandronate arm developed osteonecrosis of the jaw.https://t.co/CxhZcTNLhU

— Paolo Tarantino (@PTarantinoMD) April 21, 2022